Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Perspective Therapeutics (CATX) over the last 16 years, with Q3 2025 value amounting to 19347.92%.

  • Perspective Therapeutics' EBIT Margin fell 131365800.0% to 19347.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 14200.48%, marking a year-over-year decrease of 157144900.0%. This contributed to the annual value of 6464.15% for FY2024, which is 36091300.0% down from last year.
  • Perspective Therapeutics' EBIT Margin amounted to 19347.92% in Q3 2025, which was down 131365800.0% from 14057.89% recorded in Q2 2025.
  • Perspective Therapeutics' EBIT Margin's 5-year high stood at 238.19% during Q4 2023, with a 5-year trough of 19347.92% in Q3 2025.
  • Its 5-year average for EBIT Margin is 4075.13%, with a median of 456.68% in 2023.
  • In the last 5 years, Perspective Therapeutics' EBIT Margin soared by 1018400bps in 2021 and then crashed by -148909600bps in 2024.
  • Quarter analysis of 5 years shows Perspective Therapeutics' EBIT Margin stood at 58.06% in 2021, then crashed by -322bps to 245.08% in 2022, then surged by 197bps to 238.19% in 2023, then crashed by -6252bps to 14652.77% in 2024, then crashed by -32bps to 19347.92% in 2025.
  • Its EBIT Margin was 19347.92% in Q3 2025, compared to 14057.89% in Q2 2025 and 10201.87% in Q1 2025.